On Monday, January 15th, nearly 200 business leaders and professionals in the biopharmaceutical sector gathered at the sectoral table during the ‘Expectations 2024’ breakfast, in an effort to address the challenges and prospects of the current year in Navarra.

In a business landscape marked by geopolitical risks and challenges in digitization and artificial intelligence, executives from prominent companies such as Cinfa, Ardena Pamplona, Geiser Pharma, 3P Biopharmaceuticals, and Ojerpharma agreed on the need for “stability” and “bold measures” to face current challenges and accelerate the energy transition.

Despite the difficulties of the past year, Navarre companies have shown remarkable resilience, investing and growing both organically and inorganically. Verónica Madrid, General Manager of Geiser Pharma, shared the company’s optimistic vision, highlighting a 26% growth in revenue and a 24% increase in staff during the challenging 2023, a year in which it expanded its international presence, establishing itself in Mexico and Brazil.

Furthermore, it projects a solid growth of 10% for the year 2024, supported by an ambitious 90% of investments dedicated to innovative research and development (R&D) projects. This strategic step reflects the company’s long-term vision, anticipating continuous growth in the future. Verónica Madrid, CEO of Geiser Pharma, advocated for supporting small and medium-sized enterprises (SMEs), promoting hiring incentives, and supporting international expansion. She emphasized the importance of policies that encourage R&D and corporate taxation, stating that these elements are key to sustainable success in the competitive biopharmaceutical sector. With a steadfast look forward, Geiser Pharma is preparing to lead the way in the industry with a strong focus on innovation and continuous growth.